Kenneth E. Fleisher, DDS: No financial relationships to disclose
Medication-related osteonecrosis of the jaw (MRONJ) is a condition that has created numerous dilemmas in patient management and may have a broad health impact for patients with cancer and osteoporosis. While MRONJ was initially associated with antiresorptive medications, today there is substantial data to suggest other types of drugs and comorbidities implicated in the pathogenesis. This case-based presentation will review evidence-based data and innovative strategies for diagnosis, risk assessment, prevention and management of MRONJ with related outcomes and complications.
Learning Objectives:
At the conclusion of this presentation, participants should be able to:
Describe how to navigate the oral health and medical dilemmas associated with patients who undergo antiresorptive therapy.
Review management options for patients with various stages of MRONJ and providing the best outcomes for improving oral health and quality of life.
Recognize anatomic changes, risk factors and potential complications that impact outcome when treating MRONJ.
Discuss current evidence related to the pathogenesis of osteonecrosis of the jaw.